WASHINGTON, March 31 (Reuters) - U.S. regulators will ask an advisory panel to assess heart risks from Novo Nordisk’s (NOVOb.CO) proposed diabetes drug liraglutide as well as cases of thyroid tumors seen in rodents, documents released on Tuesday said.
